VOLITIONRX LTD Update - Financial Results & Business Progress

If you follow VolitionRx, the company behind innovative blood-based diagnostic tests, here is the latest update. They recently released their financial results for 2025. Here is what you need to know.

1. The Financial Snapshot

VolitionRx is showing clear signs of growth. Here is the breakdown of their 2025 performance:

• Revenue Growth: Fourth-quarter revenue reached $0.6 million, a 133% jump from the $0.26 million reported in late 2024. Total 2025 revenue hit $1.7 million, up 40% from the previous year.
• Cost Discipline: They successfully reduced operating expenses by 17%—dropping from $23.7 million to $19.7 million.
• Bottom Line: Their annual loss narrowed by 14%, falling from $22.5 million to $19.3 million.

2. Why This Matters for Your Portfolio

For a company in the growth phase, these numbers suggest their science is successfully transitioning into a commercial business. CEO Cameron Reynolds highlighted two major milestones:

• Nu.Q® Cancer Test: This is moving toward routine use for lung cancer screening.
• Sepsis Test: This is currently part of a $7.3 million government-backed program in France, which serves as a critical real-world test for hospital adoption.

The Big Opportunity: The company is currently negotiating with about 10 major diagnostic companies to license their Nucleosomics™ technology. Securing even one of these deals would provide steady, recurring revenue and prove their business model works without the need to issue more shares, which would otherwise dilute your ownership.

3. The "Going Concern" Note

It is important to be aware that the audit report includes a "going concern" note. Simply put, auditors are flagging that the company needs more cash or sales to sustain operations, as their current cash reserves are not enough to cover the next 12 months. To bridge this gap, the company recently raised $8.3 million through a stock offering, debt financing, and government grants.

4. Key Takeaways for Investors

• The "Transformational" Window: Management expects 2025 and early 2026 to be a pivotal period. Keep a close eye on the licensing talks; these are the primary catalyst for reducing the need for further stock offerings.
• Burn Rate: The company currently spends about $1.6 million per month on research and commercialization. Monitoring their ability to lower this spend while increasing revenue is key to their long-term survival.
• Volatility: Because the company is not yet profitable and relies on external funding, the stock price will likely remain sensitive to news regarding regulatory approvals, trial data, and cash levels.

5. What to Watch Next

The company is hosting a conference call on April 1, 2026, at 8:30 a.m. ET. This is the most important event to watch, as leadership is expected to provide updates on the status of those 10 licensing deals and their cash runway for the remainder of 2026.

Bottom Line: VolitionRx is at a "prove it" stage. If you are considering an investment, the focus should be on whether they can convert their current hospital pilots and licensing negotiations into signed, revenue-generating contracts.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and is not professional investment advice. Always do your own research before making any trades.